Literature DB >> 25296736

Decreased expression of EFS is correlated with the advanced prostate cancer.

Selda Sertkaya1, Syed Muhammad Hamid, Nihat Dilsiz, Lokman Varisli.   

Abstract

Prostate cancer is the most frequently diagnosed malignant neoplasm in men in the developed countries. Although the progression of prostate cancer and the processes of invasion and metastasis by tumor cells are comparatively well understood, the genes involved in these processes are not fully determined. Therefore, a common area of research interest is the identification of novel molecules that are involved in these processes. In the present study, we have used in silico and experimental approaches to compare the expression of embryonal Fyn-associated substrate (EFS) between normal prostate and prostate cancer. We showed that EFS expression is remarkably downregulated in prostate cancer cells, compared to normal prostate cells. We also found that decreased expression of EFS in prostate cancer cells is due to DNA methylation. In addition, we showed that high EFS expression is important to suppress a malignant behavior of prostate cancer cells. Therefore, we suggest that EFS should be considered as a novel tumor suppressor gene in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25296736     DOI: 10.1007/s13277-014-2703-5

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  34 in total

1.  CpG island promoter methylation and silencing of 14-3-3sigma gene expression in LNCaP and Tramp-C1 prostate cancer cell lines is associated with methyl-CpG-binding protein MBD2.

Authors:  S M Pulukuri; J S Rao
Journal:  Oncogene       Date:  2006-06-19       Impact factor: 9.867

2.  Gene expression analysis of prostate cancers.

Authors:  Jian-Hua Luo; Yan Ping Yu; Kathleen Cieply; Fan Lin; Petrina Deflavia; Rajiv Dhir; Sydney Finkelstein; George Michalopoulos; Michael Becich
Journal:  Mol Carcinog       Date:  2002-01       Impact factor: 4.784

Review 3.  Sin: good or bad? A T lymphocyte perspective.

Authors:  Konstantina Alexandropoulos; Laura T Donlin; Luzhou Xing; Adam G Regelmann
Journal:  Immunol Rev       Date:  2003-04       Impact factor: 12.988

4.  Identification of new genes downregulated in prostate cancer and investigation of their effects on prognosis.

Authors:  Lokman Varisli
Journal:  Genet Test Mol Biomarkers       Date:  2013-04-27

5.  Counting clonogenic assays from normoxic and anoxic irradiation experiments manually or by using densitometric software.

Authors:  An Wouters; Bea Pauwels; Hilde A J Lambrechts; Greet G O Pattyn; Johan Ides; Marc Baay; Paul Meijnders; Filip Lardon; Jan B Vermorken
Journal:  Phys Med Biol       Date:  2010-03-05       Impact factor: 3.609

6.  Androgen regulated HN1 leads proteosomal degradation of androgen receptor (AR) and negatively influences AR mediated transactivation in prostate cells.

Authors:  Lokman Varisli; Ceren Gonen-Korkmaz; Hamid Muhammad Syed; Nuray Bogurcu; Bilge Debelec-Butuner; Burcu Erbaykent-Tepedelen; Kemal Sami Korkmaz
Journal:  Mol Cell Endocrinol       Date:  2011-12-06       Impact factor: 4.102

7.  Deficiency in expression of the signaling protein Sin/Efs leads to T-lymphocyte activation and mucosal inflammation.

Authors:  Laura T Donlin; Nichole M Danzl; Celestine Wanjalla; Konstantina Alexandropoulos
Journal:  Mol Cell Biol       Date:  2005-12       Impact factor: 4.272

8.  Coordinate activation of c-Src by SH3- and SH2-binding sites on a novel p130Cas-related protein, Sin.

Authors:  K Alexandropoulos; D Baltimore
Journal:  Genes Dev       Date:  1996-06-01       Impact factor: 11.361

9.  Gene expression correlates of clinical prostate cancer behavior.

Authors:  Dinesh Singh; Phillip G Febbo; Kenneth Ross; Donald G Jackson; Judith Manola; Christine Ladd; Pablo Tamayo; Andrew A Renshaw; Anthony V D'Amico; Jerome P Richie; Eric S Lander; Massimo Loda; Philip W Kantoff; Todd R Golub; William R Sellers
Journal:  Cancer Cell       Date:  2002-03       Impact factor: 31.743

10.  A novel Cas family member, HEPL, regulates FAK and cell spreading.

Authors:  Mahendra K Singh; Disha Dadke; Emmanuelle Nicolas; Ilya G Serebriiskii; Sinoula Apostolou; Adrian Canutescu; Brian L Egleston; Erica A Golemis
Journal:  Mol Biol Cell       Date:  2008-02-06       Impact factor: 4.138

View more
  6 in total

Review 1.  Embryonal Fyn-associated substrate (EFS) and CASS4: The lesser-known CAS protein family members.

Authors:  Alexander Deneka; Vladislav Korobeynikov; Erica A Golemis
Journal:  Gene       Date:  2015-06-26       Impact factor: 3.688

2.  DNA methylome and transcriptome analysis established a model of four differentially methylated positions (DMPs) as a diagnostic marker in esophageal adenocarcinoma early detection.

Authors:  Weilin Peng; Guangxu Tu; Zhenyu Zhao; Boxue He; Qidong Cai; Pengfei Zhang; Xiong Peng; Shuai Shi; Xiang Wang
Journal:  PeerJ       Date:  2021-05-07       Impact factor: 2.984

3.  11-Ketotestosterone is the predominant active androgen in prostate cancer patients after castration.

Authors:  Gido Snaterse; Lisanne F van Dessel; Job van Riet; Angela E Taylor; Michelle van der Vlugt-Daane; Paul Hamberg; Ronald de Wit; Jenny A Visser; Wiebke Arlt; Martijn P Lolkema; Johannes Hofland
Journal:  JCI Insight       Date:  2021-06-08

4.  DNA hypermethylation associated with upregulated gene expression in prostate cancer demonstrates the diversity of epigenetic regulation.

Authors:  Ieva Rauluseviciute; Finn Drabløs; Morten Beck Rye
Journal:  BMC Med Genomics       Date:  2020-01-08       Impact factor: 3.063

5.  Systematic Elucidation of the Aneuploidy Landscape and Identification of Aneuploidy Driver Genes in Prostate Cancer.

Authors:  Yun Peng; Yuxuan Song; Haitao Wang
Journal:  Front Cell Dev Biol       Date:  2022-01-21

6.  LogLoss-BERAF: An ensemble-based machine learning model for constructing highly accurate diagnostic sets of methylation sites accounting for heterogeneity in prostate cancer.

Authors:  K Babalyan; R Sultanov; E Generozov; E Sharova; E Kostryukova; A Larin; A Kanygina; V Govorun; G Arapidi
Journal:  PLoS One       Date:  2018-11-02       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.